AQST (aquestive.com) מכפיל EV/Sales

Aquestive Therapeutics (AQST) demonstrates independence from market cycles due to low demand elasticity and patent protection. The business generates revenue from innovative soluble films for the treatment of allergies and epilepsy. The EV/Sales ratio helps assess the market's reaction to these successes, while the 10752.25 metric reflects current dynamics. Stable sales and the defensive qualities of the neurological segment minimize inflationary risks.
Aquestive Corp - פילוחים אנליטיים ומדדי מפתח (AQST)

This ratio combines market capitalization and net debt, benchmarking them against annual sales volume. The metric measures the total enterprise value, adjusted for debt load, relative to generated revenue. For Aquestive Therapeutics (AQST), with its high-margin soluble films, this calculation confirms the commercialization efficiency of its unique products. The trend in enterprise value to revenue allows for an assessment of the company's market revaluation amid high borrowing costs. It is critical for investors to track this trend to identify optimal entry points.